FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917490975> ?p ?o ?g. }

• W2917490975 endingPage "668" @default.
• W2917490975 startingPage "660" @default.
• W2917490975 abstract "Abstract Introduction Many women undergoing coronary angiography for chest pain have no or only minimal coronary artery disease (CAD). However, despite the lack of obstructive CAD, they still have an increased risk of major adverse cardiovascular events. Pleiotropic effects of statins may influence microvascular function, but if statins improve microvascular function in unselected chest pain patients is not well studied. This study assessed microvascular function by using the thermodilution‐derived test “the index of microvascular resistance” (IMR) with the aim of determining the (i) IMR level in women with chest pain and non‐obstructive CAD and if (ii) IMR is modified by high‐dose statin treatment in these patients. Additional objectives were to identify the influence of statins on the health status as assessed with generic health questionnaires and on biomarkers of endothelial activation. Materials and methods The study was a randomized, double‐blind, single‐center trial comparing 6 months of rosuvastatin treatment with placebo. In total, 66 women without obstructive CAD were included. Mean age was 52.7 years and 55.5 years in the placebo and rosuvastatin group, respectively. Microvascular function was assessed using the IMR, health status was assessed using the SF‐36 and EQ‐5D questionnaires, and biochemical values were assessed at baseline and 6 months later. Results and conclusions In the placebo group IMR was 14.6 ( SD 5.7) at baseline and 14.4 ( SD 6.5) at follow‐up. In the rosuvastatin group IMR was 16.5 ( SD 7.5) at baseline and 14.2 ( SD 5.8) at follow‐up. IMR did not differ significantly between the two study groups at follow‐up controlled for preintervention values. C‐reactive protein (CRP) was comparable between the groups at baseline, while at follow‐up CRP was significantly lower in the rosuvastatin group compared to placebo [0.6 (±0.5) mg/L vs. 2.6 (±3.0) mg/L; p = 0.002]. Whereas rosuvastatin treatment for 6 months attenuated CRP levels, it did not improve microvascular function as assessed by IMR (Clinical Trials.gov NCT 01582165, EUDRACT 2011‐002630‐39.3tcAZ)." @default.
• W2917490975 created "2019-03-02" @default.
• W2917490975 creator A5000598769 @default.
• W2917490975 creator A5003771565 @default.
• W2917490975 creator A5022181712 @default.
• W2917490975 creator A5032270444 @default.
• W2917490975 creator A5033845511 @default.
• W2917490975 creator A5039031581 @default.
• W2917490975 creator A5039625009 @default.
• W2917490975 creator A5058720661 @default.
• W2917490975 creator A5072637485 @default.
• W2917490975 creator A5076836210 @default.
• W2917490975 date "2019-02-21" @default.
• W2917490975 modified "2023-10-18" @default.
• W2917490975 title "Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double‐blind randomized study" @default.
• W2917490975 cites W183647435 @default.
• W2917490975 cites W1892017715 @default.
• W2917490975 cites W1967146205 @default.
• W2917490975 cites W1976258949 @default.
• W2917490975 cites W1979247322 @default.
• W2917490975 cites W1987468165 @default.
• W2917490975 cites W1992528636 @default.
• W2917490975 cites W1993647705 @default.
• W2917490975 cites W1994222210 @default.
• W2917490975 cites W1994957486 @default.
• W2917490975 cites W2004389112 @default.
• W2917490975 cites W2007548426 @default.
• W2917490975 cites W2032841359 @default.
• W2917490975 cites W2034179933 @default.
• W2917490975 cites W2038021282 @default.
• W2917490975 cites W2039819831 @default.
• W2917490975 cites W2040815013 @default.
• W2917490975 cites W2043983969 @default.
• W2917490975 cites W2066907392 @default.
• W2917490975 cites W2067236087 @default.
• W2917490975 cites W2068898353 @default.
• W2917490975 cites W2094983919 @default.
• W2917490975 cites W2105261018 @default.
• W2917490975 cites W2110123637 @default.
• W2917490975 cites W2116883308 @default.
• W2917490975 cites W2124624517 @default.
• W2917490975 cites W2130760108 @default.
• W2917490975 cites W2144896295 @default.
• W2917490975 cites W2152951352 @default.
• W2917490975 cites W2161822370 @default.
• W2917490975 cites W2169002600 @default.
• W2917490975 cites W2173204108 @default.
• W2917490975 cites W2186574721 @default.
• W2917490975 cites W2270949935 @default.
• W2917490975 cites W2473786944 @default.
• W2917490975 cites W2496261738 @default.
• W2917490975 cites W4292806894 @default.
• W2917490975 doi "https://doi.org/10.1002/ccd.28157" @default.
• W2917490975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30790446" @default.
• W2917490975 hasPublicationYear "2019" @default.
• W2917490975 type Work @default.
• W2917490975 sameAs 2917490975 @default.
• W2917490975 citedByCount "10" @default.
• W2917490975 countsByYear W29174909752020 @default.
• W2917490975 countsByYear W29174909752022 @default.
• W2917490975 countsByYear W29174909752023 @default.
• W2917490975 crossrefType "journal-article" @default.
• W2917490975 hasAuthorship W2917490975A5000598769 @default.
• W2917490975 hasAuthorship W2917490975A5003771565 @default.
• W2917490975 hasAuthorship W2917490975A5022181712 @default.
• W2917490975 hasAuthorship W2917490975A5032270444 @default.
• W2917490975 hasAuthorship W2917490975A5033845511 @default.
• W2917490975 hasAuthorship W2917490975A5039031581 @default.
• W2917490975 hasAuthorship W2917490975A5039625009 @default.
• W2917490975 hasAuthorship W2917490975A5058720661 @default.
• W2917490975 hasAuthorship W2917490975A5072637485 @default.
• W2917490975 hasAuthorship W2917490975A5076836210 @default.
• W2917490975 hasBestOaLocation W29174909752 @default.
• W2917490975 hasConcept C126322002 @default.
• W2917490975 hasConcept C142724271 @default.
• W2917490975 hasConcept C164705383 @default.
• W2917490975 hasConcept C204787440 @default.
• W2917490975 hasConcept C27081682 @default.
• W2917490975 hasConcept C2776839432 @default.
• W2917490975 hasConcept C2778213512 @default.
• W2917490975 hasConcept C2778704086 @default.
• W2917490975 hasConcept C2780499067 @default.
• W2917490975 hasConcept C71924100 @default.
• W2917490975 hasConceptScore W2917490975C126322002 @default.
• W2917490975 hasConceptScore W2917490975C142724271 @default.
• W2917490975 hasConceptScore W2917490975C164705383 @default.
• W2917490975 hasConceptScore W2917490975C204787440 @default.
• W2917490975 hasConceptScore W2917490975C27081682 @default.
• W2917490975 hasConceptScore W2917490975C2776839432 @default.
• W2917490975 hasConceptScore W2917490975C2778213512 @default.
• W2917490975 hasConceptScore W2917490975C2778704086 @default.
• W2917490975 hasConceptScore W2917490975C2780499067 @default.
• W2917490975 hasConceptScore W2917490975C71924100 @default.
• W2917490975 hasIssue "5" @default.
• W2917490975 hasLocation W29174909751 @default.
• W2917490975 hasLocation W29174909752 @default.
• W2917490975 hasLocation W29174909753 @default.
• W2917490975 hasLocation W29174909754 @default.

• next